Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.
Novartis AG agreed to buy British biotech Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.
Novartis AG raised $11 billion to help fund its purchase of Avidity Biosciences Inc., adding to a flurry of buyout-related bond sales.
Avidity Biosciences offices in San Diego, California, US, on Monday, Oct. 27, 2025. Novartis AG is nearing a deal to buy biotechnology company Avidity Biosciences Inc., according to a person familiar with the matter.
President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.
President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.
The Novartis AG headquarters in Basel. Photographer: Stefan Wermuth/Bloomberg
President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.
President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.
The Novartis AG headquarters in Basel. Photographer: Stefan Wermuth/Bloomberg
President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.
President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.
The Novartis AG headquarters in Basel. Photographer: Stefan Wermuth/Bloomberg
Novartis CEO Vas Narasimhan said his company has "future-proofed" against trade tensions through a $23 billion investment in the United States. He spoke to Bloomberg TV's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland. (Source: Bloomberg)
Novartis CEO Vas Narasimhan said his company has "future-proofed" against trade tensions through a $23 billion investment in the United States. He spoke to Bloomberg TV's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland. (Source: Bloomberg)
Anmelden
